Stem Cell Therapeutics Corp. (SCT) has entered into an option agreement to exclusively license worldwide rights to a series of prostate cancer stem cell assets from the University of York, UK. The assets originate from Yorkshire Cancer Research (YCR) under the direction of Professor Norman Maitland. SCT plans to work with the Maitland group, leveraging SCT’s scientific expertise and its global network of collaborators. The license agreement will contain customary terms and provisions for assets ...